Loading...
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine...  In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine...
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine ... An immunoconjugate of DM1 with huC242 (huC242-DM1; Refs. 21 and 46 ), a mAb against a glycotope on MUC1, has been recently ... In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine ... In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine ...
more infohttp://cancerres.aacrjournals.org/content/64/13/4629.long
SMART: Secondary literature for RICIN domain  SMART: Secondary literature for RICIN domain
Here we report that the high cytotoxic potency of these immunoconjugates, which is attributed to the preserved translocation ... The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ...
more infohttp://smart.embl-heidelberg.de/smart/show_secondary.cgi?domain=RICIN
Patent US20020146388 - Cytokine immunoconjugates - Google Patents  Patent US20020146388 - Cytokine immunoconjugates - Google Patents
The immunoconjugates are comprised of an immunoglobulin heavy chain having a specificity for the target cell, such as a cancer ... Nucleic acid sequences encoding these immunoconjugates and methods of their preparation by genetic engineering techniques are ... Immunoconjugates for the selective delivery of a cytokine to a target cell are disclosed. ... Immunoconjugates for the selective delivery of a cytokine to a target cell are disclosed. The immunoconjugates are comprised of ...
more infohttp://www.google.com/patents/US20020146388?dq=5,490,216
Naptumomab estafenatox: a new immunoconjugate.  Naptumomab estafenatox: a new immunoconjugate.
Immunoconjugates / adverse effects, chemistry, pharmacokinetics, pharmacology, therapeutic use*. Neoplasms / drug therapy*. ... 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Enterotoxins; 0/Immunoconjugates; 676258-98-3/naptumomab estafenatox ...
more infohttp://www.biomedsearch.com/nih/Naptumomab-estafenatox-new-immunoconjugate/20053143.html
DE602004027291D1 -   Mutated anti-CD22 antibodies and immunoconjugates   - Google Patents  DE602004027291D1 - Mutated anti-CD22 antibodies and immunoconjugates - Google Patents
Method for purifying immunoconjugates JP6162606B2 (en) 2011-01-14. 2017-07-12. レッドウッド バイオサイエンス, インコーポレイテッド. Aldehydes - tagged ... Immunoconjugates having a high binding affinity EP1263785A2 (en) 1999-11-11. 2002-12-11. THE GOVERNMENT OF THE UNITED STATES OF ... immunoconjugates. cd22 antibodies. mutated anti. mutated. anti. Prior art date. 2003-11-25. Legal status (The legal status is ... Mutated anti-CD22 antibodies and immunoconjugates ES2564092T3 (en) 2005-07-29. 2016-03-17. The Government Of The United States ...
more infohttps://patents.google.com/patent/DE602004027291D1/en
Immunoconjugate - Wikipedia  Immunoconjugate - Wikipedia
Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label. These ... Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. 2006 full article, 18 pages. Arming antibodies: ... Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. 2007 looks useful from the abstract. ...
more infohttps://en.wikipedia.org/wiki/Immunoconjugate
Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...  Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...
Antibody Immunoconjugates, Bacterial Vaccines, Immunomodulators available in on Powells.com, also read synopsis and reviews. ... Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, ...
more infohttp://www.powells.com/book/immunobiology-of-proteins-peptides-vi-9780306440380
Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...  Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines,...
Antibody Immunoconjugates, Bacterial Vaccines, Immunomodulators available in on Powells.com, also read synopsis and reviews. ... Immunobiology of Proteins & Peptides, VI: Human Immunodeficiency Virus, Antibody Immunoconjugates, Bacterial Vaccines, ...
more infohttps://www.powells.com/book/immunobiology-of-proteins-peptides-vi-9780306440380
CBR96-doxorubicin immunoconjugate - Wikipedia  CBR96-doxorubicin immunoconjugate - Wikipedia
cBR96-doxorubicin immunoconjugate (BMS-182248/SGN-15; also known as cBR96-Dox) is an antibody-drug conjugate or (ADC) directed ... Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261:212-5. ...
more infohttps://en.wikipedia.org/wiki/CBR96-doxorubicin_immunoconjugate
Mersana Therapeutics' Lead Fleximer(R) Immunoconjugate Demonstrates Potent Activity in Low HER2-Expressing Tumor Models  Mersana Therapeutics' Lead Fleximer(R) Immunoconjugate Demonstrates Potent Activity in Low HER2-Expressing Tumor Models
Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously ... XMT-1522 is a novel HER2-targeting therapy based on Mersana's Fleximer® immunoconjugate technology that carries an average of ... Mersana Therapeutics' Lead Fleximer(R) Immunoconjugate Demonstrates Potent Activity in Low HER2-Expressing Tumor Models. ... "XMT-1522, our lead clinical immunoconjugate candidate, exemplifies the significant advantages of Mersana's Fleximer platform. ...
more infohttps://www.cnbc.com/2015/04/17/globe-newswire-mersana-therapeutics-lead-fleximerr-immunoconjugate-demonstrates-potent-activity-in-low-her2-expressing-tumor-models.html
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer - Drugs.com MedNews  Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer - Drugs.com MedNews
Home › News › Clinical Trials › Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal ... Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer. Print this page ... In another colon cancer model, MST for the immunoconjugate treatment group increased 4-fold to 86 days compared to untreated ... "More preclinical evidences are being collected to support the human testing of this new drug immunoconjugate," she added.. ...
more infohttps://www.drugs.com/clinical_trials/immunomedics-announces-preclinical-therapy-results-sn-38-immunoconjugate-colorectal-cancer-6627.html
Gadolinium at carbon 60-(ZME-018) immunoconjugate targeting of A375  Gadolinium at carbon 60-(ZME-018) immunoconjugate targeting of A375
Each immunoconjugate was exposed to two cancer cell lines, A375m (a ZME-018-specific line), and T24, a bladder carcinoma line. ... Internalization of the immunoconjugate was measured at various timepoints, after which the cells were harvested and digested ... ICP-MS results show immunoconjugate internalization peaked in the first hour of exposure of the cells with a large dropoff ... For the first time, C60-monoclonal antibody (mAb) immunoconjugates have been determined to internalize into target cells using ...
more infohttps://scholarship.rice.edu/handle/1911/62174
Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for...  Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for...
synthesis; macrocyclic; polyaminocarboxylates; preparing; stable; radiometal; antibody; immunoconjugates; therapy; spect; pet; ... Title: Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates ... Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for ... Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for ...
more infohttps://www.osti.gov/doepatents/biblio/869952
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma  Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced ... A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced ...
more infohttp://www.knowcancer.com/cancer-trials/NCT00051571/
Applications filed at May 03 2018 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | Patents.com  Applications filed at May 03 2018 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | Patents.com
IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS. The conjugate compositions and methods are useful to elicit/augment ...
more infohttp://patents.com/ap-20180503-p77.html
Plus it  Plus it
Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells. Hong Zhou, John ... ITEM4-rGel immunoconjugate administration promoted long-term tumor growth suppression in nude mice bearing T-24 human bladder ... We then developed an immunoconjugate containing a high-affinity anti-Fn14 monoclonal antibody (ITEM-4) conjugated to ... Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells ...
more infohttp://mct.aacrjournals.org/content/early/2011/05/14/1535-7163.MCT-11-0161
Plus it  Plus it
In this study, a site-specific immunoconjugate, designated CYT-356, of the prostate-reactive monoclonal antibody 7E11-C5 was ... These findings suggest that the CYT-356 immunoconjugate may be useful in the diagnosis and therapy of prostate cancer. ... The native antibody and the site-specific immunoconjugate exhibited similar patterns of reactivity with normal human tissues. ... Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate ...
more infohttp://cancerres.aacrjournals.org/content/50/19/6423
Neovascular-Targeted Immunoconjugates - Patent application  Neovascular-Targeted Immunoconjugates - Patent application
... immunoconjugate or on ice for the G71-1 immunoconjugate; the control cells were incubated without added immunoconjugate. After ... G71-1 immunoconjugate than for the mfVIIasm immunoconjugate. The concentration of each immunoconjugate increased after the ... cells bind the mfVIIasm immunoconjugate but not the G71-1 immunoconjugate. The Fc effector domain of the immunoconjugate for ... 0086] Synthesis of Immunoconjugates in CHO Cells [0087] The procedures for transfecting the immunoconjugate cDNAs into CHO ...
more infohttp://www.patentsencyclopedia.com/app/20120082686
Therapeutic and Safety Evaluation of the CoMiX immunoconjugates as a novel complement activation-based immunotherapy strategy |...  Therapeutic and Safety Evaluation of the CoMiX immunoconjugates as a novel complement activation-based immunotherapy strategy |...
In the present PoC project, we will study in vivo the therapeutic efficacy of our lead CoMiX immunoconjugates in Her2 tumour ... Our novel immunoconjugates, called CoMiX (COmplement Multimer Immunotherapeutic compleXes), demonstrate in vitro higher ... Therapeutic and Safety Evaluation of the CoMiX immunoconjugates as a novel complement activation-based immunotherapy strategy. ...
more infohttps://www.fnr.lu/projects/therapeutic-and-safety-evaluation-of-the-comix-immunoconjugates-as-a-novel-complement-activation-based-immunotherapy-strategy/
Doxorubicin immunoconjugate CBR96. Definition | WikBio  Doxorubicin immunoconjugate CBR96. Definition | WikBio
Doxorubicin immunoconjugate CBR96. Definition of -Doxorubicin immunoconjugate CBR96. Meaning of -Doxorubicin immunoconjugate ... Doxorubicin immunoconjugate CBR96A substance being studied in the treatment of cancer. A combination of a monoclonal antibody ... Doxorubicin immunoconjugate CBR96. Definition. Medical Definition: -Doxorubicin immunoconjugate CBR96. A substance being ...
more infohttp://wikbio.com/en/dictionary/definition-of/-Doxorubicin-immunoconjugate-CBR96
CD37-Binding Molecules and Immunoconjugates Thereof - Patent application  CD37-Binding Molecules and Immunoconjugates Thereof - Patent application
IMMUNOCONJUGATES [0162] The present invention is also directed to conjugates (also referred to herein as immunoconjugates), ... In some embodiments, the immunoconjugate further comprises a second (C). In some embodiments, the immunoconjugate further ... the immunoconjugate comprises 2-6 (C). In some embodiments, the immunoconjugate comprises 3-4 (C). [0032] In some embodiments, ... the immunoconjugates have an average of about 3.5 (C) per (A). In some embodiments, the immunoconjugates have an average of ...
more infohttp://www.patentsencyclopedia.com/app/20120276119
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates  Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
In a comparison of the in vivo distribution of the new immunoconjugate with other tin-based immunoconjugates in tumor-bearing ... The immunoconjugates were subsequently astatinated, resulting in both high radiochemical yield and high specific activity. The ... In a comparison of the in vivo distribution of the new immunoconjugate with other tin-based immunoconjugates in tumor-bearing ... The immunoconjugates were subsequently astatinated, resulting in both high radiochemical yield and high specific activity. The ...
more infohttps://research.chalmers.se/publication/233513
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell...  Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell...
These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [3H]GA were ... These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [3H]GA were ... These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [3H]GA were ... These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [3H]GA were ...
more infohttps://einstein.pure.elsevier.com/en/publications/immunoconjugates-of-geldanamycin-and-anti-her2-monoclonal-antibod-2